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Abstract
‘Microtubule-associated protein tau’ (MAPT), ‘granulin’ (GRN) and ‘chromosome 9 open
reading frame72’ (C9ORF72) genemutations are the major known genetic causes of fronto-
temporal dementia (FTD). Recent studies suggest that mutations in these genes may also
be associated with other forms of dementia. Therefore we investigated whetherMAPT,
GRN andC9ORF72 genemutations are major contributors to dementia in a random, unse-
lected Turkish cohort of dementia patients. A combination of whole-exome sequencing,
Sanger sequencing and fragment analysis/Southern blot was performed in order to identify
pathogenicmutations and novel variants in these genes as well as other FTD-related genes
such as the ‘chargedmultivesicular body protein 2B’ (CHMP2B), the ‘FUS RNA binding
protein’ (FUS), the ‘TAR DNA binding protein’ (TARDBP), the ‘sequestosome1’ (SQSTM1),
and the ‘valosin containing protein’ (VCP). We determinedone pathogenicMAPTmutation
(c.1906C>T, p.P636L) and one novel missense variant (c.38A>G, p.D13G). InGRNwe
identified a probably pathogenic TGAG deletion in the splice donor site of exon 6. Three
patients were found to carry the GGGGCC expansions in the non-coding region of the
C9ORF72 gene. In summary, a complete screening for mutations inMAPT,GRN and
C9ORF72 genes revealed a frequency of 5.4% of pathogenicmutations in a random cohort
of 93 Turkish index patients with dementia.
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Introduction
Frontotemporal dementia (FTD) is associated with frontal and temporal lobe degeneration
resulting in progressive personality/behaviour changes, and impairment of language functions
[1]. FTD can be pathologically describedbased on the accumulation of abnormal protein as tau
positive or tau-negative/ubiquitin-positive inclusions (comprising TAR DNA-binding protein
43 and FUS inclusions). The most common genetic causes of FTD are mutations in ‘microtu-
bule-associated protein tau’ (MAPT), ‘granulin’ (GRN), and hexanucleotide repeat expansions
in ‘chromosome 9 open reading frame72’ (C9ORF72). These mutations account for 20–30% of
the familial and 5–10% of sporadic FTD cases [2].
TheMAPT gene is localizedon chromosome 17q21 and consists of 16 exons [3]. In the
human brain, tau has six different isoforms that are generated by alternative splicing of exons 2, 3,
and 10. In addition to these isoforms, splicing of exons 4a, 6 and 8 also produce differentMAPT
transcripts not being expressed in the central nervous system. AlthoughMAPTmutations, which
account for 2–11% of all FTD cases [4], are mainly found in individuals with typical FTD, muta-
tions in individuals with progressive supranuclear palsy (PSP), corticobasal degeneration (CBD),
mild late-onset parkinsonism, and dementia with epilepsy, have also been identified [5]. Most
mutations are located in exons 9–13 encoding the microtubule binding domains (that mediate
interaction of Tau with microtubules) and flanking regions. The vast majority of the mutations
includemissense, deletion or silent mutations or mutations located close to the splice donor site
of intron 10. Thesemutations show their effect through a toxic gain of functionmechanism, either
by reducing the ability of Tau to interact with microtubules or by affecting exon 10 splicing [6].
The GRN gene is located on chromosome 17q21 and consists of 13 exons of which the first
exon and part of exons 2 and 13 are noncoding. Progranulin (PGRN) protein is involved in
development, wound repair, inflammation and tumour genesis [7]. In the central nervous sys-
tem, PGRN is expressed in the cerebral cortex, the hippocampus and the cerebellum; hence
reduced levels of PGRN could affect both neuronal survival and central nervous system inflam-
matory processes [8]. The clinical spectrumof FTD associated with GRNmutations includes
the behavioural variant (bvFTD), primary progressive aphasia (PPA), and dementia associated
with movement disorders such as parkinsonism including corticobasal syndrome. The fre-
quency of GRNmutations in FTD populations varies between 5–10% [9, 10].
GGGGCChexanucleotide expansions in the first intron of the C9ORF72 gene have been
recently shown to be the most common genetic abnormality in FTD and amyotrophic lateral
sclerosis (ALS). Repeat expansions were observed in 7–11% of all FTD and 12–25% of familial
cases [11]. Prevalence differences can be seen among distinct geographical regions and there is
a significant clinical heterogeneity within families [11]. The clinical phenotype associated with
these expansions is mostly characterized by FTD symptoms and signs of motor neuron disease.
The clinical presentation may be initially diagnosed as Alzheimer’s disease (AD), mild cogni-
tive impairment (MCI), or dementia with Lewy bodies (DLB) [12]. The minimal size of a
GGGGCCpathogenic repeat is under debate: some studies consider repeats of>30 GGGGCC
hexanucleotide repeat units as pathogenic, whereas others use a cut-off of 60 GGGGCChexa-
nucleotide repeat units [13]. Currently, the detailed pathobiologicalmechanisms of the
C9ORF72 gene repeat expansion in neurodegeneration is not totally understood.
In early stages, AD and FTDmay share clinical features, at times making it difficult to dif-
ferentiate between the two diseases. Several recent studies reportedmutations inMAPT,GRN
and C9ORF72 associated with clinically diagnosedAD patients [2,13]. Cruchaga and colleagues
suggested in their study that in late-onset AD, mutations inMAPT and GRNmay be as com-
mon as mutations in ‘amyloid beta precursor protein’ (APP), ‘presenilin 1’ (PSEN1), and ‘prese-
nilin 2’ (PSEN2), the classical gene mutations associated with familial AD [14].
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In order to determine the frequency of genetic mutations in theMAPT,GRN and C9ORF72
genes in the Turkish dementia patient population, we used a combination of different sequenc-
ing and expansion analyses techniques in a cohort of 95 dementia patients from 93 families,
clinically diagnosedmostly with AD (n = 54, 56.8%) or FTD (n = 28, 29.5%). Additionally, we
also searched for mutations in other, much less frequent FTD-related genes such as the
‘charged multivesicular body protein 2B’ (CHMP2B), the ‘FUS RNA binding protein’ (FUS), the
‘TAR DNA binding protein’ (TARDBP), the ‘sequestosome1’ (SQSTM1), and the ‘valosin con-
taining protein’ (VCP).
Materials andMethods
The study was approved by the Ethics Committee of Istanbul Faculty of Medicine, Istanbul
University. A neurologist took the necessary clinical information after obtaining informed
written consent from the patients and their participating family members. Consent was pro-
vided by the Legally Authorized Representative for subjects unable to consent.
Our initial cohort of dementia patients (n = 105) was originally assessed for definitely path-
ogenic classifiedmutations in PSEN1 (NM_000021) (n = 6), PSEN2 (NM_000447) (n = 0) and
APP (NM_001204302) (n = 0) [15]. Further investigations revealed the c.3691C>T (p.R1231C)
‘neurogenic locus notch homolog protein 3’ (NOTCH3) (NM_000435)mutation to cause clini-
cally diagnosedAD in one particular family [16]. Furthermore, ‘triggering receptor expressed on
myeloid cells 2’ (TREM2) (NM_018965)homozygous mutations [c.97C>T (p.Q33X),
c.197C>T (p.T66M), c.113A>G (p.Y38C)] were identified in three families presenting an
atypical FTD phenotype [17]. The remaining 93 families comprising 95 patients where the
above mutations were not found, were diagnosed clinically mostly either with AD (56.8%) or
FTD (29.5%), other dementia forms (13.7%) beingmore rare (Table 1).
All participants were recruited consecutively over 24 months (2010–2012) in the Beha-
vioural Neurology and Movement Disorders Unit outpatient clinic in Istanbul Faculty of Medi-
cine, Istanbul University and underwent detailed clinical and neuropsychological examination
Table 1. Characteristics of the cohortof dementia patients analysed for mutations inMAPT,GRN and
C9ORF72.
Number (n) of families and patients 93 families (95 patients)
Diagnoses (n of patients) AD (n = 54; 56.8%); FTD (n = 28; 29.5%); DLB (n = 6; 6.3%); PDD
(n = 2; 2.1%); CBD (n = 1; 1.1%); other dementias (n = 4, including
PCA (n = 2; 2.1%), and PSP (n = 2; 2.1%))
Geographical origin (n of patients) TR (74), TR/GR (2), TR/RO (1), TR/AF (1), TR/RUS (1), BG (4), CS
(4), GR (2), BG/GR (2), RO (1), AL/MK (1), BG/RO (1), RO/UA (1)
Age at examination, average (range) 69.3 years (45–89)
Age at onset, average (range) 63.9 years (38–84)
Gender 60 females (63.2%), 35 males (36.8%)
Patients with known family history of
dementia
61 (64.2%)
Patients with known parental first
degree consanguinity
9 (9.4%)
Patients with suspected parental
consanguinity
40 (42%)
AD: Alzheimer’s disease, FTD: frontotemporal dementia, DLB: dementia with Lewy bodies, PDD:
Parkinson’s disease with dementia, CBD: cortical basal degeneration, PCA: posterior cortical atrophy, PSP:
progressive supranuclear palsy, TR: Turkey, BG: Bulgaria,GR: Greece, MK: Macedonia, RO: Romania, UA:
Ukraine, AF: Afghanistan, RUS: Russia, CS: Serbia and Montenegro, AL: Albania
doi:10.1371/journal.pone.0162592.t001
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and, in most cases cerebral magnetic resonance imaging (cMRI) or positron emission tomogra-
phy (PET) imaging. The diagnosis of dementia was based on the National Institute of Neuro-
logical and Communicative Disorders and Stroke and Alzheimer’s disease [18], FTD was
defined following the criteria of International Behavioural Variant FTD Criteria Consortium
[19] and the criteria developed by an international group of PPA investigators [20] and the
diagnosis of DLB was made based on the consensus guidelines from the DLB consortium [21].
Diagnostic procedures for Parkinson’s disease dementia (PDD) followed the recommendations
of the movement disorder society task force [22]. The study population was comprised of 60
female and 35 male patients with a mean age at onset of clinical signs of 63.9 ± 9.8 years (age
ranges 38–84 years). Positive family history of dementia was reported in 64.2% (n = 61) of
patients, 9.4% (n = 9) of the patients had parents known to be cousins and in 42% (n = 40)
parental consanguinity of different degrees was suggested. Family history was considered as
positive if at least a first or a second degree related family member was also known to suffer
from dementia. To the best of our knowledge, none of the relatives of our patients was diag-
nosed with ALS. Most families originated from Turkey (n = 79 (85%), Table 1). Peripheral
blood samples were collected and genomic deoxyribonucleic acid (DNA) was extracted by
standard procedures using the Qiagen DNA isolation maxi kit (Qiagen, Hilden, Germany).
Genetic analysis
Whole-exome sequencing (WES). The DNA samples were sequenced in one flow cell
lane each, on paired end 50–base pair HiSeq 2000 runs (Illumina Inc), following capture using
Illumina’s TruSeq Exome Capture Kit -62Mb (Illumina, Inc) and yielding an average of about
6 billion high-quality (Phred score> = 20) bases per sample. This amount of data represented
the average mean target coverage of 55x, with an average percentage of targets covered greater
or equal to 10x of 59%. Sequence reads were mapped to the reference genome (human genome
19) using the Burrows-Wheeler aligner [23]. Single-nucleotide polymorphisms (SNPs) and
insertions and deletions (indels) were called using the Genome Analysis Toolkit (GATK) v2.7
[24]. Visual inspection of variants was performed,when necessary, using the Integrative Geno-
mics Viewer (IGV) v2.0 [25].
Variants were annotated using Single Nucleotide Polymorphism database (dbSNP) 138 and
functional annotation was done using snpEff [26]. Variants within the genes of interest,MAPT
(NM_001123066.3),GRN (NM_002087.2),C9ORF72 (NM_018325),FUS (NM_001170937),
TARDBP (NM_007375),SQSTM1 (NM_003900.4),VCP (NM_007126) and CHMP2B
(NM_014043),were extracted for further analyses. The genes analysed presented an individual
average coverage of>33x and exons in specific samples with coverage below 8x were Sanger
sequenced. In order to identify potentially pathogenic variants, we assessed the frequency of the
variants in the general population (Exome Aggregation Consortium (ExAC), dbSNP, 1000
Genomes Project) but they were not genotyped in a control cohort from the same population.
We also evaluated the functional annotation of the variants (if the variants were synonymous,
predicted to change the protein sequence or were located in either untranslated or splicing
regions) and the prediction of pathogenicity (using prediction software).We considered as
potentially pathogenic variants those with minor allele frequency (MAF)< = 0.1% (rare vari-
ants), predicted to change the protein sequence or to impact splicing.Mutations were considered
to be definitely pathogenic if they had previously been reported in the literature as causative, or
if segregation analysis confirmedpathogenicity. One new identifiedMAPT variant (c.38A>G, p.
D13G) that was absent in the above mentioned populations was additionally searched in the
‘The Scientific and Technological Research Council of Turkey’ (TUBITAK)-Advanced genome
and bioinformatics research centre in-house exome database of varying disorders, including
Major FTDGeneMutations in Turkish Patients
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neurodegenerative diseases. The data set spans 1182 individuals from Turkey who were not only
genotyped for this variant, but whole exome-sequenced as part of rare disease studies. Given the
high degree of consanguinity in the studied population we also used a filter for variants zygosity
in order to analyse any homozygous variants of interest in these genes.
Sanger sequencing. We performed Sanger sequencing to confirm potentially pathogenic
variants found by WES in the probands, to test family members and to sequence any exons with
low coverage inWES. Exons were amplified by polymerase chain reaction (PCR; primers and
conditions are available on request) using Roche FastStart PCRMaster Mix polymerase (Roche
Diagnostics Corp). The PCR products were sequenced using the same forward and reverse
primers with Applied Biosystems BigDye terminator version 3.1 sequencing chemistry and run
on an ABI3730XL genetic analyzer as per the manufacturer’s instructions (Applied Biosystems).
The sequences were analysed using Sequencher software, version 4.2 (Gene Codes).
Repeat-primedPCR. To screen GGGGCChexanucleotide expansions in the C9ORF72
gene, repeat-primed PCR was carried out as previously described [27]. Fragment length analy-
sis was performed on an ABI 3730xl genetic analyser (Applied Biosystems, Foster City, CA,
USA), and data were analyzed using GeneMapper software. Patients were compared to a posi-
tive control sample.
Southern blot. A total of 10 μg of gDNA was digested with XbaI and HindIII at 37°C for
3–5 hours and electrophoresed in 0.8% agarose gel. For size determination, DNA size standards
λBstEII and 2.5 kb ladder were added. After electrophoresis, the coordinates of the size stan-
dards were transferred to a stripe of white paper for the subsequent analysis of the sample
results. DNA was transferred to positively charged nylon membrane. Following pre-hybridiza-
tion in Church buffer at 71°C for 3 hours, hybridization was carried out at 71°C overnight. The
blot was hybridized with a random primed-α32P-dCTP-labeled probe flanking the hexanucleo-
tide repeat [28]. The membranes were then washed in 1% sodium dodecyl sulphate (SDS) and
0.5 M Na-Phosphate at 56–58°C. The membranes were exposed to X-ray films for 4 days at
-70°C applying an intensifying screen. For measurement of the expanded alleles, the marker
data (migration distance and size) from the paper stripes were transferred to semi-logarithmic
graph paper. A regression curvewas plotted by connecting all data points. The hybridization
signals of the X-ray filmwere also transferred to the semi-logarithmic graph paper, pinpointing
the size of the expanded (and normal) alleles.
Results
InMAPT exon 10 we found the pathogenic c.1906C>T (p.P636L) mutation in one patient
diagnosedwith FTD (Fig 1). In addition, 10 variants previously reported as non-pathogenic
and 1 newmissense variant (p.D13G) were identified (Table 2).
We identified a deletion (c.708+6_9delTGAG) in the splice donor site of GRN exon 6 in one
patient with clinically diagnosedAD (Fig 2, S1 and S2 Figs). Alamut software (Interactive-Bio-
software, Rouen, France), which integrates different splice site prediction tools (MaxEntScan,
NNSPLICE, Human Splicing Finder, SpliceSiteFinder, GeneSplicer), was used to investigate
the splicing effect of this variant. These tools predicted that c.708+6_9delTGAG variant could
decrease the splicing of exon 6 by 44.3%, 7.6%, 2.2%, 6.1% and 39.7%, respectively, due to
decreased 5’ donor site score. Two different previously reported variants with unclear pathoge-
nity [c.415T>C (p.C139R), c.626C>T (p.P209L)] and 6 non-pathogenic changes were found
(Table 3).
Three patients showed large C9ORF72 hexanucleotide expansions (Table 4, S4 Fig). Segre-
gation analysis could be performed in one family that had multiple family members with psy-
chotic features (FTD-18, S5 Fig). Clinical details of family FTD-18 can be found in the
Major FTDGeneMutations in Turkish Patients
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S1 Table. In addition, we determined two patients with C9ORF72 variants: c.1138T>G (p.
F380V) and c.146C>G (p.T49R) (S2 Table). The former variant was identified in a Turkish
patient with typical late-onset AD (74 years) who passed away in her 5th year of follow up. The
p.F380V variant was not found in the exome variant server (EVS), dbSNP, or ExAC databases
and classified as “possibly damaging”, “damaging” and “disease causing”, by the three predic-
tion programs PolyPhen-2, SIFT and MutationTaster respectively. The secondC9ORF72mis-
sense variant p.T49R found in another AD patient did not segregate with the disease (the
affected sister was a non-carrier) and the variant was classified as ‘benign/neutral’ by the in sil-
ico prediction (PolyPhen-2, SIFT). In addition, the variant is reported in the EVS (0.0154),
dbSNP (0.0001731), and ExAC (0.0002) databases.
We have also identified a hexanucleotide deletion in the FUS gene at the intron 5 splice donor
site in a patient diagnosedwith AD (S2 Table). The deletion has been reported previously and
found not pathogenic based on its presence in healthy controls. In line with this, this variant was
predicted to be benign according to in silico prediction programs, SIFT andMutationTaster.
No other pathogenic mutation in genes known to be associated with neurodegenerative dis-
eases, and/or rare genetic causes of dementia, such as mutations in CHMP2B, FUS, TARDBP,
SQSTM1 and VCP have been identified. Furthermore, 23 variants in the VCP (n = 10),
C9ORF72 (n = 7), CHMP2B (n = 3) and FUS (n = 3) genes were detected, but none of them
revealed as pathogenic (S2 Table).
Discussion
In this study we performed a combination of WES and Sanger sequencing to identify patho-
genic mutations and novel variants inMAPT and GRN, and fragment length analysis/Southern
blot to detect pathogenic C9ORF72 expansions in a Turkish cohort of dementia patients, the
majority with a family history and shown not to carry ‘classical’ AD gene mutations. Our anal-
ysis revealed the pathogenic mutation (p.P636L) in exon 10 ofMAPT, localized in one of the
microtubule binding domains where most of the known pathogenicMAPTmutations are
found [29]. Thep.P636L mutation has been reported in more than 30 families mainly in associ-
ation with autosomal-dominant FTD, although various types of clinical presentations have
been described [29]. The clinical presentation of our patient diagnosedwith bvFTD is
Fig 1. PD-158 family pedigree and sequencingchromatograms. (A) The arrow indicates the proband. Black filled symbols: patients
affected with FTD; grey symbol: Alzheimer’s disease, white symbols: unaffected family members, N: normal,M: the p.P636L mutation, AO:
age at disease onset, AD: age of death (B) Sequencing chromatograms of patients II-6 and II-7 showing theMAPT p.P636L mutation region.
doi:10.1371/journal.pone.0162592.g001
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comparable to previous findings. His age at onset of clinical symptoms (62 years) and his age at
death (67 years) were higher than the reportedmean ages of onset and death for this mutation
(52.6 and 59.3 years, respectively) [29]. The same mutation was not found in his older brother,
who developed the first clinical signs much later (75 vs 62 years) and also presented a different
phenotype that was compatible with a diagnosis of AD, despite the fact that vascular involve-
ment (heart insufficiencyand carotid plaques) played a significant role in his disease (Fig 1).
However, additional molecular risk or co-factors responsible for the development of neurode-
generation in this family cannot be excluded.
Furthermore, we identified one newmissense variant, in exon 1 (p.D13G) (Table 2): So far,
the only mutations reported in exon 1 are the c.14G>A (p.R5H) [30] and the c.14G>T (p.
R5L) [31], both related to a phenotype compatible with PSP. Our patient carrying the p.D13G
variant had a positive family history compatible with autosomal-dominant inheritance and
presented with AD. One healthy brother was found to be a non-carrier. However, the variant
was not reported in the large databases and also not found in the ‘TUBITAK’-Advanced
genome and bioinformatics research centre in-house exome database of varying disorders. It
was classified as ‘probably damaging’ or ‘damaging’ by the prediction software (Table 2). In
addition, the variant is located at a highly conservedposition and might also affect the interac-
tion of tau with tubulin and tau microtubules as it has been shown for the closely located p.R5L
and p.R5H mutations [30, 31]. On this basis we suggest that the p.D13G variant is possibly
pathogenic and in that case, the clinical presentation of our patient expands the clinical spec-
trum for mutation carriers in exon 1. However, another missense variant, located on the same
amino acid (c.37G>A, p.D13N) has been reported in the ExAC database and replication and
functional studies are needed to confirm our findings.
The prevalence ofMAPT-related disorders in general is not very well known; several studies
suggest that the frequency ofMAPTmutations varies between 0 and 17.8% depending on the
population [32, 33]. Taking into account FTD patients with a positive family history of demen-
tia the frequencymay increase up to 40% [33]. Our analysis revealed a mutation in theMAPT
gene in 3.6% (1/28) of patients with FTD. This is similar to the results of previous studies per-
formed in Sweden, US, France and US populations with reported frequencies of 0, 1.2, 2.9 and
Fig 2. ALZ-6 family pedigree and sequencingchromatograms. (A) The arrow indicates the proband. Black filled symbols: affected patients;
white symbols: unaffected family members. N: Normal,M: the c.708+6_9delTGAG deletion. CVA: cerebral vascular accident, AO: age at
disease onset, AD: age of death. (B) Sequencing chromatograms show the presence of GRN c.708+6_9delTGAG deletion in the index patient
III-3 that is not seen in individuals III-1 and III-4.
doi:10.1371/journal.pone.0162592.g002
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Table 3. GRN nonsynonymous variants and allele frequencies.
All
samples
(n = 95)
FTD
samples
(n = 28)
AD
samples
(n = 54)
All (n = 95) Familial
(n = 61)
All (n = 28) Familial
(n = 20)
All (n = 54) Familial
(n = 31)
Variant/rs ID CADD
(PHRED
scaled)
In silico
Prediction*
Domain Diagnosis Counts
(%)
Counts
(%)
Counts
(%)
Counts
(%)
Counts
(%)
Counts
(%)
MAF**
Pathogenic
c.708
+6_9delTGAG/
na
na Weakens
normal***
DSS
InterFB FTD(n = 1) 1/95 (1.1) 1/61 (1.6) 1/28 (3.6) 1/20 (5) 0/54 (0) 0/31 (0) na/na/na
Unclear
pathogenicity
c.415T>C; p.
C139R/na
15.14 PrD/D/DC GranF FTD(n = 1) 1/95 (1.1) 1/61 (1.6) 1/28 (3.6) 1/20 (5) 0/54 (0) 0/31 (0) na/
0.0002/
na
c.626C>T; p.
P209L/
rs368995988
14.76 PrD/T/DC GrnB PCA
(n = 1)
1/95 (1.1) 1/61 (1.6) 0/28 (0) 0/20 (0) 0/54 (0) 0/31 (0) 0.008/
0.0005/
0.0002
Non pathogenic
c.99C>A; p.
D33E/
rs63750742
21.4 B/T/P ParaGran FTD(n = 1) 1/95 (1.1) 1/61 (1.6) 1/28 (3.6) 1/20 (5) 0/54 (0) 0/31 (0) na/
6.612e-
05/0.001
c.229G>A; p.
V77I/
rs148531161
6.656 B/T/P GranG FTD(n = 1) 1/95 (1.1) 0/61 (0) 1/28 (3.6) 1/20 (5) 0/54 (0) 0/31 (0) 0.008/
0.0001/
0.0006
c.359C>A; p.
S120Y/
rs63750043
9.072 B/D/P InterGF AD(n = 1) 1/95 (1.1) 0/61 (0) 0/28 (0) 0/20 (0) 1/54 (1.9) 0/31 (0) 0.02
/0.0008/
na
c.545C>T; p.
T182M/
rs63750479
8.353 B/T/P InterFB AD(n = 1) 1/95 (1.1) 0/61 (0) 0/28 (0) 0/20 (0) 1/54 (1.9) 0/31 (0) 0.3/
0.001/
0.002
c.1193C>T; p.
S398L/
rs148213321
14.45 B/T/P GranC FTD(n = 1) 1/95 (1.1) 0/61 (0) 1/28 (3.6) 0/20 (0) 0/54 (0) 0/31 (0) 0.008/
7.552e-
05/na
c.1544G>C; p.
G515A/ rs25647
5.254 B/T/P InterDE AD(n = 1) 1/95 (1.1) 0/61 (0) 0/28 (0) 0/20 (0) 1/54 (1.9) 0/31 (0) 1.02/
0.003/
0.005
5’UTR variants
c.-203G>C/
rs555738837
14.35 na/na/na UTR AD(n = 2) 2/95 (2.1) 1/61 (1.6) 0/28 (0) 0/20 (0) 2/54 (3.7) 1/31 (3.2) na/na/na
c.-22C>T/
rs572309824
12.4 na/na/P UTR FTD(n = 1) 1/95 (1.1) 1/61 (1.6) 1/28 (3.6) 1/20 (5) 0/54 (0) 0/31 (0) na/na/na
c.-12C>G/na na na/na/P UTR PSP
(n = 1)
1/95 (1.1) 1/61 (1.6) 0/28 (0) 0/20 (0) 0/54 (0) 0/31 (0) na/na/na
c.-8+46G>T/
rs564341543
7.7 na/na/P UTR FTD(n = 2) 2/95 (2.1) 2/61 (3.3) 2/28 (7.1) 2/20 (10) 0/54 (0) 0/31 (0) na/na/
0.0002
*In silico prediction programs (PolyPhen-2, SIFT, MutationTaster, respectively) were used to evaluate the effect of nonsynonymous variants on protein
function and structure.
**Minor allele frequency (MAF, %) information provided from exome variant server (EVS) / ExAC / dbSNP, respectively.
***Variant was analysed using the splicing function in Alamut software.
Exon numbering startswith noncoding first exon EX 0; Numbering according to the largestGRN transcript (GenBank Accession Number NM_002087.2);
Numberingaccording to the largestGRN isoform (GenPept Accession Number NP_005901.2). Abbreviations: B:benign, D:damaging, DC:disease causing,
P:polymorphism, PrD:probably damaging, PsD:possibly damaging T:tolerated, na: not available; DSS: donor splice site.
doi:10.1371/journal.pone.0162592.t003
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5.9%, respectively [34, 35, 10, 31]. However, our frequency in FTD patients with positive family
history of dementia was relatively low (5%, 1/20) compared to other studies with frequencies of
25, 33.3, and 40.5% respectively [36, 37, 33]. No pathogenicMAPTmutations were identified
in our AD patients.
In theGRN gene we identified a deletion (c.708+6_9delTGAG) near the splice donor site of
exon 6 (Fig 2, S1 Fig). This known deletion occurs in a repeat sequence (GTGAGTGA) located
in the exon-intron 6 boundary. Two different studies identified similar deletions in the same
repeat sequence in different positions [38, 39]. In both cases, the deletions were identified in
neuropathologicaly confirmed FTD patients with TDP-43 positive inclusions. The clinical phe-
notype, the age at onset (60 vs mean onset: 63.5 years), and the disease evolution of our patient
are similar to previously published findings [38, 39]. Both parents of our patient died at around
80 years, the father of a cerebral vascular accident and a cousin was reported to have cognitive
impairment (Fig 2). Skoglund and colleagues (2011) reported that the IVS6+5_8delGTGA
deletion either causes skipping of exon 6 (V200GfsX18) or retention of intron 6 (A237VfsX17)
[38]. In addition, TGAG deletion carriers had modestly reduced brain mRNA levels when
compared with a control patient [39]. These results are consistent with previous findings of
other pathogenicGRN null mutations [40]. It is also noteworthy that the c.708+1G>Cmuta-
tion nearby has been previously reported as pathogenic; therefore, altered splicing of exon 6 is
a known pathogenic mechanism [9, 41].
We identified two additional variants in the GRN gene with uncertain pathogenicity (p.
C139R, p.P209L). The variant p.C139R had been previously described in three families; an Ital-
ian early-onset familial FTD patient [42], a Belgian late-onset AD patient [43] and a late-onset
familial FTD patient [44]. Based on protein modelling, p.C139R was predicted to be likely
pathogenic because it affects folding of the PGRN by disrupting one of the cysteine disulphide
bridges [36]. In addition, low plasma PGRN levels were reported in carriers of p.C139R sug-
gesting a partial loss of PGRN function [37]. So far, though, the pathogenic nature of the muta-
tion has not been proven by segregation analysis. We have identified this variant in a patient
suffering from FTD at age of 70 years who died at age of 77 years. The patient was part of a
very large family with a clear autosomal-dominant inheritance, including at least 5 more
known to be affected, but already deceased family members (S3 Fig). Further analysis of addi-
tional family members failed to confirm a clear pheno- and genotype correlation in our family.
However, the healthy reported variant carriers have not yet reached the age of disease onset
(51, 49 and 47years) and could develop clinical symptoms.
No segregation analysis could be performed for the other unclear variant (p.P209L).
In the 5’ UTR of GRN we identified four variants:
The known c.-8+46G>T variant located in the promoter region is predicted to alter tran-
scription factor binding site and has been reported in one patient with early-onset FTD (49
years) [45]. In our study this variant was observed in two families: the first patient was diag-
nosed with PPA and the second family was previously described by Lohmann et al. (2012) car-
rying the probably pathogenic PSEN1 c.784T>G (p.L262V) mutation that segregated with the
Table 4. Clinical information of theC9ORF72 expansion carriers.
Patient Gender Origin Age at onset (years) Family history Clinical diagnosis
AD-55 Female Turkey 63 positive FTD (PNFA)*
AD-81 Male Macedonia 57 positive FTD (PNFA)*
FTD-18 (II-7) Female Turkey 61 positive behavioural FTD
*progressive non-fluent aphasia
doi:10.1371/journal.pone.0162592.t004
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disease [15]. Based on the non-segregation of the c.-8+46G>TGRN variant with the disease,
and the additional occurrence of the probably pathogenic PSEN1 p.L262V mutation in the
same family, we consider this GRN variant to be not pathogenic. Different studies suggested
that variants in the 5’ regulatory region can change transcriptional activity through altered
transcription factor binding sites resulting in the reduction of GRN expression [10, 40, 45].
They can also effect the splicing of intron 0 causing a non-functional transcript [40]. Changes
in GRN transcriptional activity caused by variants in the promoter regionmight be a risk factor
for the disease pathogenesis. However further gene studies are needed to show the precise effect
of the promoter variants on GRN transcriptional activity.
The c.-22C>T variant was co-segregatingwith the p.C139R substitution in the family dis-
cussed above (S3 Fig). The segregation analysis of the other two variants (c.-203G>C, c.-
12C>G) identified in the 5’ UTR region could not be performed due to lack of DNA from
additional family members.
The frequency of 3.6% (1/28) pathogenicGRNmutations in our FTD cohort was very simi-
lar to previously described findings [10, 46]. Various studies showed an occurrence of GRN
mutations between 1.3 and 11.7% [47]. Interestingly, the frequency of FTD patients with a pos-
itive family history of dementia was considerably lower compared to other studies showing an
occurrence up to 25.6% [47]. No unclear or pathogenicGRN variants were found in patients
diagnosedwith AD in our cohort, except the p.P209L variant that was found in a patient with
posterior cortical atrophy.
In C9ORF72we identified repeat expansions in 3 among 95 patients. These 3 cases presenting
large expansion sizes showed clinical symptoms compatible with either behavioural or aphasic
FTD (Table 4). Ages at onset ranged between 57 and 63 years and all of them had a positive fam-
ily history compatible with autosomal-dominant inheritance. Co-segregationof the expansion
and cognitive impairment in one of our families was explored (S1 Table, S5 Fig): By examining
with revisedAddenbrooke’s cognitive examination (ACE-R) the expansion-carrying children of
the index patient (S5 Fig, S1 Table, II-7), we could observe a tendency to lower performance com-
pared to non-carriers. Interestingly, many members of this family suffered frommajor depres-
sion, obsessive-compulsive disorder, specific and social phobia (S5 Fig, S1 Table). Psychosis and
obsessive-compulsive disorder are often reported as early neuropsychiatric features in C9ORF72-
associated bvFTD [48], but the symptoms did not segregated with the C9ORF72 expansion in
our family suggesting a different origin. To the best of our knowledge, the GGGGCChexanucleo-
tide repeats are the only proven pathogenic variants in C9ORF72 reported to date and no other
mutations are known. Further studies will be necessary to confirm our findings.
Our study showed that the total frequency of C9ORF72 repeat expansions is 3.2% (3/93) in
our cohort of dementia patients and 10.7% (3/28), when only taking into account patients diag-
nosed with FTD, but increasing to 15% (3/20) in FTD patients with a positive family history of
dementia consistent with previously reported percentages [11, 49]. All togetherC9ORF72
repeat expansions seem to be as frequent in Turkish FTD patients, as in other cohorts [11].
Given the high degree of families with consanguinity, we also suggested the possible pres-
ence of mutations. However at least in our cohort we could not confirm any autosomal reces-
sive transmission due to the absence of homozygous variants classified as pathogenic. In
addition, we could not find any pathogenic mutation neither in the CHMP2B, FUS, TARDBP,
SQSTM1 nor in the VCP genes, confirming their rarity also in a cohort from Turkey.
Conclusion
This is the first molecular study in a Turkish cohort of dementia patients analysing the main
FTD-related genes.MAPT,GRN and C9ORF72 pathogenic mutations are not uncommon in
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our population with different types of dementia (5.4%, 5/93). When these data is combined
with data we have previously published [15, 16, 17] we conclude that among 105 dementia
patients, 5.7% are attributable to PSEN1mutations (6/105), 2.9% (3/105) to C9ORF72 and
TREM2 each, and 0.95% (1/105) toMAPT, GRN and NOTCH3 each, while 85.7% (90/105)
remain unclear.
In this study, only taking into account patients diagnosedwith FTD (n = 28), the frequency
of clearly pathogenicMAPT,GRN and C9ORF72mutations was found to be 17.8% (5/28)
showing that the frequency of bothMAPT and GRNmutations is lower compared to previous
findings suggesting that mutations in these genes account only for a small subset of patients in
Turkey.
Looking at all results, it is apparent that 3 patients initially diagnosedwith AD, including
one patient with the visual variant of AD (posterior cortical atrophy), are carriers of variants in
the FTD genes (MAPT,GRN and C9ORF72) while 5 patients diagnosedwith FTD carried
mutations in the AD-related PSEN1 gene [15]. However, 3 of the patients with FTD initially
received the diagnosis of AD before further disease development led to the diagnosis of FTD.
Our results suggest that due to the heterogeneity and wide range of clinical presentation of
both AD and FTD, routine genetic analyses should not be restricted to the well established AD
or FTD genes, but use a more global approach including genes to be involved in different
dementias.
Given the frequency of variants identified inMAPT,GRN and C9ORF72, but also in our
previous analysis of PSEN1, PSEN2 and APP, in the Turkish cohort of dementia patients stud-
ied, a standardizedmolecular screening procedure for these genes should be implemented in
Turkey. The high birth rate expected for this and the next generation in Turkey make these
studies of particularly importance given the potential high impact in genetic counseling and
clinical management of FTD and dementia families.
Supporting Information
S1 Fig. Integrative genomics viewer (IGV) display of the c.708+6_9delTGAG deletion in
GRN. The 4-bp deletion is indicated by thin black lines.
(TIFF)
S2 Fig. In silico splicing effect analysis of GRN c.708+6_9delTGAG variant using Alamut
software.The exonic regions are drawn as blue boxes. Scores from each mutation prediction
tool are displayed in blue vertical bars for 5' (donor) sites, and as green vertical bars for 3' (accep-
tor) sites. Known constitutive signals are displayed as small blue (5') or green (3') triangles.
(TIF)
S3 Fig. Pedigree of the FTD-16 Family carrying theGRN c.415T>C (p.C139R) and c.-
22C>T variants.The arrow indicates the proband. Black filled symbols: affected patients; dark
grey symbol: depressive mood; light grey symbol: mild cognitive impairment; white symbol:
unaffected family members; N: wild type; M: c.415T>C (p.C139R) and c.-22C>T carrier.
(TIFF)
S4 Fig. Image of Southern blot analysis.
(TIF)
S5 Fig. Pedigree of the FTD-18 Family carrying the C9ORF72 repeat expansion.The arrow
identifies the proband; dark grey symbol: major depression; light grey symbol: obessive-com-
pulsive disorder; dark blue: mental retardation; M: C9ORF72 expansion carrier;N: wild type.
(TIFF)
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S1 Table. Clinical phenotype of the assessed family FTD18 members. cut-off score: 86 for
age< 60 years and education> 12 years.
(DOCX)
S2 Table. Variants identified in C9ORF72, CHMP2B, FUS, TARDBP, VCP genes and syn-
onymous variants inMAPT,GRN. na: not available; dbSNP: single nucleotide polymorphism
database; ID: identification.
(DOCX)
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